Your browser doesn't support javascript.
loading
Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.
Young, Lucy C; Goldstein de Salazar, Ruby; Han, Sae-Won; Huang, Zi Yi Stephanie; Merk, Alan; Drew, Matthew; Darling, Joseph; Wall, Vanessa; Grisshammer, Reinhard; Cheng, Alice; Allison, Madeline R; Sale, Matthew J; Nissley, Dwight V; Esposito, Dominic; Ognjenovic, Jana; McCormick, Frank.
Afiliação
  • Young LC; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94153.
  • Goldstein de Salazar R; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94153.
  • Han SW; Department of Internal Medicine, Seoul National University Hospital, Seoul 03080, Republic of Korea.
  • Huang ZYS; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94153.
  • Merk A; National Cryo-EM Program, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.
  • Drew M; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.
  • Darling J; National Cryo-EM Program, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.
  • Wall V; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.
  • Grisshammer R; National Cryo-EM Program, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.
  • Cheng A; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94153.
  • Allison MR; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94153.
  • Sale MJ; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94153.
  • Nissley DV; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.
  • Esposito D; National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.
  • Ognjenovic J; National Cryo-EM Program, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702.
  • McCormick F; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94153.
Proc Natl Acad Sci U S A ; 120(5): e2208960120, 2023 Jan 31.
Article em En | MEDLINE | ID: mdl-36689660
The majority of pathogenic mutations in the neurofibromatosis type I (NF1) gene reduce total neurofibromin protein expression through premature truncation or microdeletion, but it is less well understood how loss-of-function missense variants drive NF1 disease. We have found that patient variants in codons 844 to 848, which correlate with a severe phenotype, cause protein instability and exert an additional dominant-negative action whereby wild-type neurofibromin also becomes destabilized through protein dimerization. We have used our neurofibromin cryogenic electron microscopy structure to predict and validate other patient variants that act through a similar mechanism. This provides a foundation for understanding genotype-phenotype correlations and has important implications for patient counseling, disease management, and therapeutics.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neurofibromatose 1 / Neurofibromina 1 Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neurofibromatose 1 / Neurofibromina 1 Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article